Aster DM Healthcare (ASTERDM) Q2 24/25 earnings summary

Executive summary

• Achieved strong growth in Q2 and H1 FY25, outpacing industry benchmarks with robust operational and financial performance across all clusters.

• Strategic realignment, capacity expansion, and operational efficiencies have driven sustained momentum and profitability.

• Leadership changes, board expansion, and ESOP grants aim to strengthen governance and support growth initiatives.

• Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY25, following a technical delay from domain migration.

• Statutory auditor issued an unmodified review report for both standalone and consolidated results.

Financial highlights

• India revenue grew 16% year-over-year to INR 1,086 crores in Q2 FY25; H1 FY25 revenue up 18% to INR 2,088 crores.

• Operating EBITDA rose 48% year-over-year to INR 233 crores in Q2 FY25, with margin at 21.4%; H1 FY25 EBITDA up 44% to INR 410 crores, margin at 19.6%.

• PAT post NCI doubled to INR 97 crores in Q2 FY25 and to INR 171 crores in H1 FY25; consolidated net profit for Q2 FY25 was INR 105.76 crores.

• Material costs (ex-wholesale pharmacy) reduced to 20.7% in H1 FY25 from 22.8% a year ago.

• Net cash position at INR 988 crores as of September 30, 2024; consolidated cash and cash equivalents at INR 914.57 crores.

Outlook and guidance

• Expect continued margin expansion, targeting 21%+ consolidated EBITDA margin and 24%+ for hospital and clinic segment over the next 2–3 years.

• ARPOB growth projected at 7–8% CAGR over the medium term, driven by price increases, improved payer mix, and operational efficiencies.

• Strategic focus on brownfield and greenfield expansion, niche specialties, operational efficiency, and digital transformation.

• Andhra and Telangana cluster margins expected to reach 20%+ in 2–3 years; Karnataka and Maharashtra to maintain 300–400 bps higher margins than Kerala.

• Continued investment in labs, pharmacies, and technology to enhance patient outcomes and reach.